Cargando…

FOXC1 Binds Enhancers and Promotes Cisplatin Resistance in Bladder Cancer

SIMPLE SUMMARY: In bladder cancer, cisplatin remains the front-line therapy, but drug resistance is common. Previously, we showed that cancer cells can spontaneously convert to an aggressive drug-resistant phenotype without mutational events. In the current work, we explored the epigenetic mechanism...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Yi-Tsung, Xu, Tong, Iqbal, Maheen, Hsieh, Tien-Chan, Luo, Zhifei, Liang, Gangning, Farnham, Peggy J., Rhie, Suhn K., Goldkorn, Amir
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996937/ https://www.ncbi.nlm.nih.gov/pubmed/35406487 http://dx.doi.org/10.3390/cancers14071717

Ejemplares similares

m(6)A epitranscriptome analysis reveals differentially methylated transcripts that drive early chemoresistance in bladder cancer
por: Hodara, Emmanuelle, et al.
Publicado: (2023)

The Enigmatic HOX Genes: Can We Crack Their Code?
por: Luo, Zhifei, et al.
Publicado: (2019)

Bladder cancer cells shift rapidly and spontaneously to cisplatin-resistant oxidative phosphorylation that is trackable in real time
por: Xu, Tong, et al.
Publicado: (2022)

ZFX acts as a transcriptional activator in multiple types of human tumors by binding downstream from transcription start sites at the majority of CpG island promoters
por: Rhie, Suhn Kyong, et al.
Publicado: (2018)

Genome-wide analysis of HOXC4 and HOXC6 regulated genes and binding sites in prostate cancer cells
por: Luo, Zhifei, et al.
Publicado: (2020)

CRISPR-mediated deletion of prostate cancer risk-associated CTCF loop anchors identifies repressive chromatin loops
por: Guo, Yu, et al.
Publicado: (2018)

A high-resolution 3D epigenomic map reveals insights into the creation of the prostate cancer transcriptome
por: Rhie, Suhn Kyong, et al.
Publicado: (2019)

Identification of activated enhancers and linked transcription factors in breast, prostate, and kidney tumors by tracing enhancer networks using epigenetic traits
por: Rhie, Suhn Kyong, et al.
Publicado: (2016)

Endothelial FOXC1 and FOXC2 promote intestinal regeneration after ischemia–reperfusion injury
por: Tan, Can, et al.
Publicado: (2023)

TENET 2.0: Identification of key transcriptional regulators and enhancers in lung adenocarcinoma
por: Mullen, Daniel J., et al.
Publicado: (2020)

Foxc1 and Foxc2 in the Neural Crest Are Required for Ocular Anterior Segment Development
por: Seo, Seungwoon, et al.
Publicado: (2017)

Loss of Foxc1 and Foxc2 function in chondroprogenitor cells disrupts endochondral ossification
por: Almubarak, Asra, et al.
Publicado: (2021)

The prostate cancer risk variant rs55958994 regulates multiple gene expression through extreme long-range chromatin interaction to control tumor progression
por: Qian, Yuyang, et al.
Publicado: (2019)

FOXC2-AS1/FOXC2 axis mediates matrix stiffness-induced trans-differentiation of hepatic stellate cells into fibrosis-promoting myofibroblasts
por: Sun, Liankang, et al.
Publicado: (2023)

All eyes on FOXC2
por: Yan, Wei, et al.
Publicado: (2023)

Ezh2-dCas9 and KRAB-dCas9 enable engineering of epigenetic memory in a context-dependent manner
por: O’Geen, Henriette, et al.
Publicado: (2019)

FOXC2 Promotes Vasculogenic Mimicry in Ovarian Cancer
por: Recouvreux, Maria Sol, et al.
Publicado: (2022)

MCM3AP-AS1 promotes cisplatin resistance in gastric cancer cells via the miR-138/FOXC1 axis
por: Sun, Han, et al.
Publicado: (2021)

Stanniocalcin 1 promotes metastasis, lipid metabolism and cisplatin chemoresistance via the FOXC2/ITGB6 signaling axis in ovarian cancer
por: Lin, Feikai, et al.
Publicado: (2022)

Foxc2 is essential for podocyte function
por: Nilsson, Daniel, et al.
Publicado: (2019)

Regulation and Function of FOXC1 in Osteoblasts
por: Suthon, Sarocha, et al.
Publicado: (2023)

Foxc1 is required by pericytes during fetal brain angiogenesis
por: Siegenthaler, Julie A., et al.
Publicado: (2013)

Shear stimulation of FOXC1 and FOXC2 differentially regulates cytoskeletal activity during lymphatic valve maturation
por: Norden, Pieter R, et al.
Publicado: (2020)

Rewiring of cisplatin-resistant bladder cancer cells through epigenetic regulation of genes involved in amino acid metabolism
por: Yeon, Austin, et al.
Publicado: (2018)

Foxc1 and Foxc2 function in osteochondral progenitors for the progression through chondrocyte hypertrophy and mineralization of the primary ossification center
por: Almubarak, Asra, et al.
Publicado: (2023)

Characterizing chromatin interactions of regulatory elements and nucleosome positions, using Hi-C, Micro-C, and promoter capture Micro-C
por: Lee, Beoung Hun, et al.
Publicado: (2022)

Correction: Characterizing chromatin interactions of regulatory elements and nucleosome positions, using Hi‑C, Micro‑C, and promoter capture Micro‑C
por: Lee, Beoung Hun, et al.
Publicado: (2023)

Novel FOXC2 Mutation in Hereditary Distichiasis Impairs DNA-Binding Activity and Transcriptional Activation
por: Zhang, Leilei, et al.
Publicado: (2016)

FOXC1, the new player in the cancer sandbox
por: Elian, Fahed A., et al.
Publicado: (2017)

The Diverse Consequences of FOXC1 Deregulation in Cancer
por: Gilding, L. Niall, et al.
Publicado: (2019)

Structural basis for DNA recognition by FOXC2
por: Chen, Xiaojuan, et al.
Publicado: (2019)

Current status of liquid biopsies for the detection and management of prostate cancer
por: Lu, Yi-Tsung, et al.
Publicado: (2019)

Molecular and computational approaches to map regulatory elements in 3D chromatin structure
por: Lee, Beoung Hun, et al.
Publicado: (2021)

Using 3D epigenomic maps of primary olfactory neuronal cells from living individuals to understand gene regulation
por: Rhie, Suhn K., et al.
Publicado: (2018)

FOXC1 and FOXC2 maintain mitral valve endothelial cell junctions, extracellular matrix, and lymphatic vessels to prevent myxomatous degeneration
por: Tan, Can, et al.
Publicado: (2023)

FOXC1 is involved in ERα silencing by counteracting GATA3 binding and is implicated in endocrine resistance
por: Yu-Rice, Yi, et al.
Publicado: (2016)

Data supporting the regulation of FOXC2 in podocyte dysfunction
por: Datta, Neeta, et al.
Publicado: (2016)

FOXC1: an emerging marker and therapeutic target for cancer
por: Han, Bingchen, et al.
Publicado: (2017)

Crystal Structure of FOXC2 in Complex with DNA Target
por: Li, Shichang, et al.
Publicado: (2019)

FOXC2 augments tumor propagation and metastasis in osteosarcoma
por: Gozo, Maricel C., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_vruf7gib9r898k7nnp1s59m84p